Product Information
SUCRALFATE 1 GM/10 ML SUSP is a generic product labeled by VistaPharm, LLC, priced at $0.1163 per ML under NDC 66689030516. Its NADAC has been published 220 times since Jul 20, 2022.
FDA first approved this application on Mar 15, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 g/10mL
Manufacturer
VistaPharm, LLCNDC
66689030516
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUCRALFATEApproval Type
Generic (ANDA)
FDA Application
ANDA211884FDA Approved
3/15/2022
TE Code
AB
On Market Since
3/15/2022
Pharmacological Classes
Price Statistics
The NADAC for SUCRALFATE 1 GM/10 ML SUSP has been published 220 times since Jul 20, 2022, and over the history we have for it it has declined 65.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1163 per ML |
|---|---|
| All-time high | $0.3648 (Nov 16, 2022) |
| All-time low | $0.0907 (Jan 21, 2026) |
| 52-week high | $0.1253 |
| 52-week low | $0.0907 |
| Median price | $0.2703 |
| Average price | $0.2422 |
| Largest weekly change | -14.9% (Sep 17, 2025) |
| Weeks tracked | 220 |
| Tracking since | Jul 20, 2022 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
VistaPharm, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sucralfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aluminum Complex class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUCRALFATE 1 GM/10 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for SUCRALFATE 1 GM/10 ML SUSP, manufactured by VistaPharm, LLC, is $0.1163 per ML (NDC 66689030516), effective Sep 30, 2026.
How has the price of SUCRALFATE 1 GM/10 ML SUSP changed over time?
Over the history we have for it, the NADAC for SUCRALFATE 1 GM/10 ML SUSP has declined 65.0%. It has been tracked across 220 weekly CMS publications since Jul 20, 2022.
What are the highest and lowest recorded NADAC prices for SUCRALFATE 1 GM/10 ML SUSP?
Since Jul 20, 2022, the NADAC for SUCRALFATE 1 GM/10 ML SUSP has ranged from a low of $0.0907 (Jan 21, 2026) to a high of $0.3648 (Nov 16, 2022), with a median of $0.2703 per ML.
Are there cheaper alternatives to SUCRALFATE 1 GM/10 ML SUSP?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SUCRALFATE 1 GM/10 ML SUSP, is $0.1153 per ML — about 1% below SUCRALFATE 1 GM/10 ML SUSP.
Who manufactures SUCRALFATE 1 GM/10 ML SUSP?
SUCRALFATE 1 GM/10 ML SUSP (NDC 66689030516) is labeled by VistaPharm, LLC, and CMS classifies it as a generic product.